Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
The Methodist Hospital Research Institute
Study ID
NCT00440973
Phase
PHASE2
Status
Terminated

Conditions

  • Carcinoma, Renal Cell

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    monoclonal antibody with anti-angiogenesis properties used as chemotherapy
  • Interleukin-2 — DRUG
    immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T \& B lymphocyte proliferation

Study Details

The purpose of this study is to determine if the combination of therapy to strengthen the immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can prolong the time between the start of treatment and disease progression, decrease tumor size, as well as determine if the combination therapy is safer and less toxic than the standard treatment for renal cell carcinoma.

Key Dates

First listed
Feb 27, 2007
Start date
Oct 31, 2006
Status verified
Mar 2016
Primary completion
Oct 31, 2007
Completion
Nov 30, 2007

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: treatment arm
    PI relocated, currently data is no longer available

Primary Outcome Measure

time to progression [ Time Frame: During study (currently data no longer available) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Baylor College of Medicine - Methodist HospitalHoustonTexas77030-

Find similar trials in Houston, TX

By research site
Baylor College of Medicine - Methodist Hospital· Houston, TX

Related Studies